{"entity":{"id":"nct01106235","kind":"trial","name":"IL-21-modulated CD8+ antigen-specific T cells with cyclophosphamide and aldesleukin in metastatic melanoma (Fred Hutchinson phase 1, terminated)","aka":[],"tldr":"A Seattle trial of melanoma-targeting T cells treated in the laboratory with the immune signal IL-21 before infusion. The registry lists it as terminated in 2011 and gives no reason.","summary":"The registry describes a phase I study of autologous interleukin-21-modulated CD8+ antigen-specific T cells, with cyclophosphamide and aldesleukin, in metastatic melanoma, started in April 2010, with an estimated enrolment of 12 (ClinicalTrials.gov NCT01106235). Its overall status is terminated, with primary completion in November 2011 and no reason for stopping recorded; Cassian Yee is listed as principal investigator (ClinicalTrials.gov NCT01106235). No results are posted.","status":"withdrawn","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT01106235","url":"https://clinicaltrials.gov/study/NCT01106235"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","aldesleukin"],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT01106235","phase":"1","setting":"Stage IV melanoma: autologous CD8+ antigen-specific T cells modulated with interleukin-21 in the laboratory, with cyclophosphamide and aldesleukin","sponsor":"Fred Hutchinson Cancer Center, with the National Cancer Institute","result":"Terminated, with no reason given on the registry; no results posted.","started":"2010-04","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01106235/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}